Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public MeetingGlobeNewsWire • 10/23/24
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of CytisiniclineGlobeNewsWire • 10/16/24
Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical AffairsGlobeNewsWire • 10/01/24
Achieve Life Sciences Announces Changes in Executive Leadership and Board of DirectorsGlobeNewsWire • 08/26/24
Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate UpdateGlobeNewsWire • 08/13/24
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine DependenceGlobeNewsWire • 07/31/24
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley BankGlobeNewsWire • 07/29/24
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024GlobeNewsWire • 07/25/24
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual MeetingGlobeNewsWire • 05/17/24
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateGlobeNewsWire • 05/09/24
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal MedicineGlobeNewsWire • 05/06/24
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024GlobeNewsWire • 04/25/24
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x ReturnsSeeking Alpha • 04/04/24
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate UpdateGlobeNewsWire • 03/28/24
Achieve Life Sciences Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 03/06/24
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA SubmissionGlobeNewsWire • 02/29/24
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 02/29/24
Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatmentMarket Watch • 12/12/23